Erschienen in:
08.03.2024 | Research
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
verfasst von:
María Gion, Juan José García-Mosquera, José Manuel Pérez-García, Vicente Peg, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, José Antonio Guerrero, Laura López-Montero, Mario Mancino, José Rodríguez-Morató, Gabriele Antonarelli, Miguel Sampayo-Cordero, Antonio Llombart-Cussac, Javier Cortés
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 3/2024
Einloggen, um Zugang zu erhalten
Abstract
Purpose
The prognostic and predictive role of trophoblast cell-surface antigen-2 (Trop-2) overexpression in human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer is currently unknown. We retrospectively analyzed Trop-2 expression and its correlation with clinicopathologic features and pathological complete response (pCR) in HER2-positive early breast cancer (EBC) patients treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab in the PHERGain study.
Methods
Trop-2 expression at baseline was determined in formalin-fixed, paraffin-embedded primary tumor biopsies by immunohistochemistry and was first classified into expressing (Trop-2-positive) or not-expressing (Trop-2-negative) tumors. Then, it was classified by histochemical score (H-score) according to its intensity into low (0–9), intermediate (10–49), and high (≥ 50). The association between clinicopathologic features, pCR, and Trop-2 expression was performed with Fisher’s exact test.
Results
Forty-one patients with tissue evaluable for Trop-2 expression were included, with 28 (68.3%) Trop-2-positive tumors. Overall, 17 (41.46%), 14 (34.15%), and 10 (24.40%) tumors were classified as low, intermediate, and high, respectively. Trop-2 expression was significantly associated with decreased pCR rates (50.0% vs. 92.3%; odds ratio [OR] 0.05; 95% CI, 0.002–0.360]; p adjusted = 0.01) but was not correlated with any clinicopathologic features (p ≥ 0.05). Tumors with the highest Trop-2 H-score were less likely to obtain a pCR (OR 0.03; 95% CI, 0.001–0.290, p adjusted < 0.01). This association was confirmed in univariate and multivariate regression analyses.
Conclusion
These findings suggest a potential role of Trop-2 expression as a biomarker of resistance to neoadjuvant chemotherapy plus dual HER2 blockade and may become a strategic target for future combinations in HER2-positive EBC patients.